| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d5c56994aa6a8fa2e454e204c32d30e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5515b14e4fcdc67fa8a5273e37a804e9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2016-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d95f7d7b88daa945b06920a116a1274a |
| publicationDate |
2016-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016131875-A1 |
| titleOfInvention |
Methods and kits for the molecular subtyping of bladder cancer |
| abstract |
The present invention relates to in vitro methods of identifying a molecular subtype of a tumor in a patient having bladder cancer and to methods of stratifying a bladder cancer patient for tumor treatment. It further relates to corresponding kits and their uses, as well as to prognostic biomarkers for bladder cancer, in particular singular prognostic biomarkers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11183286-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019207039-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10055540-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11264117-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10847252-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10847253-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020094399-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020064966-A1 |
| priorityDate |
2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |